QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
Stopped Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.
Conditions
- Pulmonary Fibrosis Secondary to Systemic Sclerosis
Interventions
- DRUG: QAX576
- DRUG: Placebo
Sponsor
Novartis Pharmaceuticals